| Literature DB >> 34783649 |
Natalia Vydra1, Patryk Janus1,2, Paweł Kus2, Tomasz Stokowy3, Katarzyna Mrowiec1, Agnieszka Toma-Jonik1, Aleksandra Krzywon1, Alexander Jorge Cortez1, Bartosz Wojtas4, Bartłomiej Gielniewski4, Roman Jaksik2, Marek Kimmel2,5, Wieslawa Widlak1.
Abstract
Heat shock factor 1 (HSF1), a key regulator of transcriptional responses to proteotoxic stress, was linked to estrogen (E2) signaling through estrogen receptor α (ERα). We found that an HSF1 deficiency may decrease ERα level, attenuate the mitogenic action of E2, counteract E2-stimulated cell scattering, and reduce adhesion to collagens and cell motility in ER-positive breast cancer cells. The stimulatory effect of E2 on the transcriptome is largely weaker in HSF1-deficient cells, in part due to the higher basal expression of E2-dependent genes, which correlates with the enhanced binding of unliganded ERα to chromatin in such cells. HSF1 and ERα can cooperate directly in E2-stimulated regulation of transcription, and HSF1 potentiates the action of ERα through a mechanism involving chromatin reorganization. Furthermore, HSF1 deficiency may increase the sensitivity to hormonal therapy (4-hydroxytamoxifen) or CDK4/6 inhibitors (palbociclib). Analyses of data from The Cancer Genome Atlas database indicate that HSF1 increases the transcriptome disparity in ER-positive breast cancer and can enhance the genomic action of ERα. Moreover, only in ER-positive cancers an elevated HSF1 level is associated with metastatic disease.Entities:
Keywords: breast cancer; cancer biology; cell biology; chromatin organization; estrogen receptor; genomic action; heat shock factor 1; human
Mesh:
Substances:
Year: 2021 PMID: 34783649 PMCID: PMC8709578 DOI: 10.7554/eLife.69843
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140